ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer
Key Highlights
- ➤Response exceeded 105 months in heavily pretreated metastatic vulvar cancer patient
- ➤Patient remains in good health with stable disease as of July 2026
- ➤Relacorilant plus nab-paclitaxel response lasted more than 20 times prior taxane regimen
- ➤Relacorilant is not approved for metastatic vulvar cancer
- ➤Lifyorli approved for platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers
Expert Statements
Pamela Munster, Professor of Medicine in Oncology and Associate Director at Stanford Cancer Institute
“Metastatic vulvar cancer is an exceptionally challenging disease to treat, and its impact on patients is profound”
Pamela Munster, Professor of Medicine in Oncology and Associate Director at Stanford Cancer Institute
“Sustained disease control continuing at eight years is a remarkable milestone in this setting and speaks to the benefit and tolerability of this regimen.”
Pamela Munster, Professor of Medicine in Oncology and Associate Director at Stanford Cancer Institute
“This case reinforces the rationale for further research into targeting glucocorticoid receptor signaling in patients with various types of solid tumors.”
Joseph K. Belanoff, M.D., Chief Executive Officer of Corcept Therapeutics
“We are grateful for the academic collaborators and partners who advance our science and deepen our understanding of glucocorticoid receptor antagonism’s potential to help patients with serious diseases, including difficult-to-treat cancers like this one.”
ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced publication of a peer-reviewed case report in ESMO Rare Cancers, regarding an approximately eight-year response to relacorilant plus nab-paclitaxel in a patient with metastatic vulvar cancer.
Get started
Create a free account to read the full story.
